Press Release

<<  Back
Printer Friendly Version   View printer-friendly version
BioTime to Present at Two Upcoming Investor Conferences
September 06, 2016

ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 6, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the following investor conferences:

  • 2016 Gateway Conference at the Four Seasons Hotel, San Francisco, Wednesday, September 7, 2016, at 11:00am ET (8:00am PT)
  • 18th Annual Rodman & Renshaw Global Investor Conference at the Lotte New York Palace Hotel, New York City, Tuesday, September 13, 2016, at 3:50pm ET (12:50pm PT)

Attendance at both conferences is by invitation only. BioTime’s management will provide a corporate overview as well as an update on its product development. Both presentations will be webcast live and available for replay at the “Events & Presentations” page of the “Investors & Media” section on BioTime’s website at

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent cell assets. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:



Source: BioTime, Inc.

BioTime, Inc.
Dan L. Lawrence, 510-775-0510
Investor Contact:
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Media Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890